These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 29716842

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Countering clinical inertia in lipid management: Expert workshop summary.
    Zullig LL, Egbuonu-Davis L, Trasy A, Oshotse C, Goldstein KM, Bosworth HB.
    Am Heart J; 2018 Dec; 206():24-29. PubMed ID: 30290290
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis.
    Dykun I, Mincu R, Hendricks S, Balcer B, Totzeck M, Rassaf T, Mahabadi AA.
    Eur J Prev Cardiol; 2020 Oct; 27(15):1675-1678. PubMed ID: 31357886
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lipidology.
    Nicholls SJ.
    Cardiol Clin; 2018 May; 36(2):xiii. PubMed ID: 29609763
    [No Abstract] [Full Text] [Related]

  • 9. Editorial Lp(a) - the underestimated cardiovascular risk factor.
    Mellwig KP.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):1. PubMed ID: 28236286
    [No Abstract] [Full Text] [Related]

  • 10. Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease.
    Methodist Debakey Cardiovasc J; 2019 Mar; 15(1):4. PubMed ID: 31049142
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z.
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction.
    Moriarty PM.
    Am J Cardiol; 2001 May 15; 87(10):1206-8; A7. PubMed ID: 11356401
    [No Abstract] [Full Text] [Related]

  • 18. [New perspectives in cardiovascular risk reduction: focus on HDL].
    Paolillo S, Della Ratta GL, Vitagliano A, Cirillo A, Lardino E, Formisano T, Fabiani I, Pellegrino AM, Riello P, Filardi PP.
    Monaldi Arch Chest Dis; 2013 Mar 15; 80(1):27-30. PubMed ID: 23923587
    [Abstract] [Full Text] [Related]

  • 19. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I, Smith G.
    Metab Syndr Relat Disord; 2012 Jun 15; 10(3):159-60. PubMed ID: 22568574
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.